PMC6343960_01
Longitudinal evaluation of hepatitis B virus (HBV)-DNA, liver enzymes, and white blood cell counts before and after ocrelizumab treatment. A, HBV-DNA, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) modifications over time during ocrelizumab treatment. B, White blood cell absolute counts and neutrophil, lymphocyte, and monocyte percentages over time during natalizumab treatment. Arrows represent ocrelizumab infusions. Horizontal dotted line: HBV-DNA lower limit of quantification (20 IU/mL). HBV-DNA was detected and quantified using the Cobas AmpliPrep/CobasTaqman HBV Test (Roche Molecular Diagnostic, Pleasanton, CA). Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ETV, entecavir; Ocre, ocrelizumab; WBC, white blood cells.
ofy356f0001.jpg
PMC6343960_01_ofy356f0001.jpg
F1
The patient remained asymptomatic, and liver enzymes and WBC counts were within normal ranges (Figure 1).